Welcome | Grunenthal Group

Improving the lives of patients is our mission. We are an ambitious and dynamic business with a healthy innovation-driven pipeline that enables us to build on our core expertise in pain. Strong ongoing partnerships with leading healthcare and development organisations bring our new products to life. This commitment to innovation and thought-leadership means that next generation scientific talent is drawn to us.

Grünenthal. Change is possible.

locations
30

We are present in 30 countries with affiliates in Europe, Latin America and the US.

market presence
100

Our products are sold in more than 100 countries.

employees
5,200

5,200 employees work for our group worldwide.


Please read more about our projects supported by resources of the European Regional Development Fund

... Read More

What we do

As a fully integrated research & development company we bring innovative pain treatments and state-of-the-art technologies to patients.

... Learn more about Grünenthal

Pioneering thinkers

Our passion is innovation. We are driven to seek new solutions for patients with severe diseases and high unmet medical needs – and make these solutions accessible to patients.
... Find out more

Careers

Ready to create a brighter future for our patients?
With us, let your passion and ideas flow and drive innovation to improve our patients’ lives.

... Work with Grünenthal

Featured news & articles

Packaging at Grünenthal
Story_Strong_roots_Aachen
This week Grünenthal took part in the annual JP Morgan Healthcare Conference. This is the place to be to come together with investors from around the world.
MyGrünenthal icon on smartphone

Medicines Verification System

We protect our patients against falsified pharmaceutical products

Grünenthal now operates in line with new EU laws that protect patients by preventing counterfeit medicines from being dispensed in pharmacies. With the successful GoLive of one of the most complex programs in the last decade, we have made a decisive contribution to increasing patients’ safety.

Author: Alexandra Paesch

Grünenthal & Aachen

Strong roots - where the heart is

In business terms, Grünenthal has come a long way since it was founded almost 75 years ago. But geographically, our company has always stayed true to its roots in Aachen and Stolberg – and it always will.

Author: Fabia Kehren

Exploring opportunities

The power of partnerships

This week Grünenthal took part in the annual JP Morgan Healthcare Conference. This is THE PLACE TO BE to come together with investors from around the world. “Motivated and energised by our latest success, we continue to explore inorganic growth opportunities and R&D partnerships for compounds in early stage development,” says Gabriel Baertschi, CEO Grünenthal. We’re committed to open collaboration with partners who share our passion for creating innovative medicines that improve patients’ quality of life.

Author: Cornelia Kompe

MyGrünenthal

Grünenthal digitally networked for the benefit of patients

More than 5,200 employees in 30 countries and from all departments of Grünenthal work together to improve the lives of patients with new, effective drugs. A close exchange is indispensable. The internal cooperation has been strengthened since the beginning of the year by "MyGrünenthal", the company's new social intranet.

Author: Barbara Wünschmann

1/22/2019

Aachen, Germany, 22 January 2019– Grünenthal announced today that Fabian Raschke has been appointed Chief Financial Officer (CFO) and Member of the Corporate Executive Board. He will assume leadership of Grünenthal’s Finance and IT organisation on 1 February 2019. Fabian currently leads Grünenthal’s Group Controlling and manages over 150 employees, including Finance staff in the affiliates.

12/14/2018

Aachen, Germany and Gothenburg, Sweden, 14 December 2018 – Grünenthal and OnDosis announced today that they have entered into an exclusive collaboration to develop the OnDosis’ technology for prescription medicines in all pain related indications. The agreement also entails an option for Grünenthal to an exclusive worldwide license to the technology in these indications. The handheld device enables individualised dosing of oral medicines in micro units, provides support for patient compliance, can be combined with digital solutions and thus significantly improves patients’ safety. The agreement with Grünenthal, a leading pain specialist, is the first partnering deal for life science startup OnDosis on their innovative technology. While this agreement covers the indication area pain; other focus areas of OnDosis, like ADHD and immunosuppression, remain available for further cooperation with third parties.

12/7/2018

Aachen, Germany, December 7, 2018 – Grünenthal is participating in the PAIN-Vis research initiative and working with the University of Cologne, the Goethe University Frankfurt and Forschungszentrum Jülich [Jülich Research Center] to create a foundation for improvements in pain diagnosis. The basic research project will receive €2.26 million from the European Regional Development Fund and the German federal state of North Rhine-Westphalia over three years from 2017 to 2020 (PAIN-Vis grant ref. EFRE-800975).

12/3/2018

Aachen, Germany, 03 December 2018 – Grünenthal today announced the successful completion of its acquisition of European rights to Nexium and global (ex US and Japan) rights to Vimovo from AstraZeneca for a total consideration of up to US$ 922 m (€ 811 m). “Today is an important day for Grünenthal,” said Gabriel Baertschi, CEO Grünenthal. “This transaction represents a significant step towards our vision of creating a world free of pain for patients. It is also is the biggest single investment in the history of our company. This transaction will double our EBITDA performance and significantly strengthen our leading position in pain management”.

11/14/2018

Aachen, Germany / Morristown, New Jersey, USA, 14 November, 2018 – Grünenthal announced today that it has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to the United States. Averitas Pharma will be commercialising the pain patch Qutenza® (8 % capsaicin) for Grünenthal in the US. Grünenthal had only recently acquired the remaining global rights, including the US rights, for the product from Acorda Therapeutics.

 
External Link:
You are now leaving the Grünenthal Group website. You will be re-directed to an external website. Grünenthal accepts no responsibility for the content of other websites. ... Cancel ... Ok